The new infrastructure at the Rochester facility in New York is part of a US$100m investment to boost production capacity
DuPont has announced the opening of a new state-of-the-art probiotics fermentation unit at its Rochester facility in New York, US.
Construction of the unit was completed in March as part of an overall US$100m investment to expand probiotics capacity.
The facility is now producing high-quality probiotics for the dietary supplement and food and beverage industries, which have the potential to provide health benefits to consumers of all ages.
“The investment in our Rochester probiotics operation furthers our strategy to provide health and nutrition science solutions to this growing market,” said DuPont CEO Marc Doyle.
“With the completion of this facility, we have the largest fermenter in the world dedicated to probiotics production, which enhances our ability to provide customers and consumers with high quality, clinically documented strains that will positively impact people’s health now and in the future.”
The state-of-the-art facility incorporates several new production innovations, including
In addition to the company’s capital investment, construction of the fermentation unit was supported by an Upstate Revitalization Initiative Grant provided by Empire State Development.
Empire State Development President, CEO and Commissioner, Howard Zemsky, said: "Supporting the growth of innovative companies such as DuPont, with its new probiotics fermentation unit at Eastman Business Park, reinforces the strength of the region’s agriculture and food ecosystem and reflects our strategic focus on recruiting and retaining food production businesses that drive economic development in the Finger Lakes.”
“We deeply appreciate the support from the state of New York as we launch this industry-leading endeavour,” said Matthias Heinzel, President of DuPont Nutrition & Biosciences.
“We’re proud to be part of the Rochester community and to expand our footprint at the Eastman Business Park. This investment represents our deep commitment to driving innovation through probiotic research and manufacturing.”